Epidemiology & Statistics
A comprehensive overview of the global burden, prevalence, incidence, demographic patterns, and geographic distribution of Parkinson’s disease, with rigorously cited data from the most authoritative epidemiological studies.
2.1 Global Prevalence & Burden
Parkinson’s disease (PD) is the fastest-growing neurological disorder in the world by both prevalence and disability-adjusted life years (DALYs). The Global Burden of Disease (GBD) 2016 study estimated 6.1 million people were living with PD globally in 2016 — more than double the 2.5 million estimated in 1990 (GBD 2016 Parkinson’s Disease Collaborators, 2018, The Lancet Neurology). By 2024, estimates have risen to approximately 10 million worldwide (Parkinson’s Foundation, 2024).
The dramatic increase in prevalence is driven by multiple factors: global population aging, improved diagnostic recognition, reduced competing mortality from cardiovascular disease, and potentially environmental exposures. Dorsey and colleagues (2018, JAMA Neurology) have described this phenomenon as a “Parkinson’s pandemic”, projecting that global PD prevalence will reach 12–17 million by 2040 under different modeling scenarios.
2.2 Incidence
The incidence of PD — the rate of new cases — shows consistent patterns across populations. In developed countries, incidence is approximately 8–18 per 100,000 person-years in the general population, rising steeply with age to 50–100 per 100,000 among those over 60 years (de Lau & Breteler, 2006, The Lancet Neurology). Approximately 90,000 new cases are diagnosed annually in the United States alone (Willis et al., 2022, npj Parkinson’s Disease), a figure substantially higher than prior estimates of ~60,000.
2.3 Age & Sex Distribution
PD is primarily a disease of older adults. Mean age at diagnosis is approximately 60–65 years. The prevalence increases exponentially with age: from approximately 0.3% in adults aged 55–64 years to over 3% in those aged 80–89 years (de Rijk et al., 2000, Neurology). However, approximately 4–10% of cases are diagnosed before age 50 — termed Young-Onset Parkinson’s Disease (YOPD) — and before age 40 are considered early-onset PD.
A consistent and robust sex difference exists: men are 1.4–2.0 times more likely to develop PD than women across nearly all studied populations (Wooten et al., 2004, Neuroepidemiology). Proposed explanations include: neuroprotective effects of estrogen on dopaminergic neurons; differences in environmental exposure patterns (particularly occupational pesticide exposure); X-linked genetic modifiers; and sex differences in immune function and neuroinflammatory responses.
2.4 Geographic & Ethnic Variation
PD prevalence and incidence vary substantially by geographic region and ethnicity. Europe and North America consistently report the highest prevalence rates; sub-Saharan Africa and East Asia historically lower rates, though this gap is narrowing as populations age and diagnostic capacity improves. A meta-analysis by Muangpaisan and colleagues (2011) found a two-fold variation in PD incidence between the highest- and lowest-incidence regions globally.
Within multiethnic populations, data are complex. Several studies in the United States suggest that Hispanic/Latino individuals may have higher PD rates than non-Hispanic White individuals, while Asian Americans have somewhat lower rates. African Americans are less likely to be diagnosed with PD despite similar or higher pathological rates — a disparity attributed to reduced healthcare access, diagnostic bias, and underrepresentation in research cohorts (Van Den Eeden et al., 2003, American Journal of Epidemiology).
2.5 Economic & Societal Burden
The economic burden of PD is substantial and growing. In the United States, the total annual economic burden — including direct medical costs, informal caregiver costs, and lost productivity — was estimated at $51.9 billion in 2017, projected to exceed $79 billion by 2037 (Yang et al., 2020, npj Parkinson’s Disease). Globally, PD contributes approximately 3.3 million DALYs annually. As populations age, these figures will escalate substantially, underscoring the urgent need for disease-modifying therapies and efficient healthcare delivery models.
References: de Lau & Breteler (2006) Lancet Neurology; Dorsey et al. (2018) JAMA Neurology; GBD 2016 PD Collaborators (2018) Lancet Neurology; Van Den Eeden et al. (2003) Am J Epidemiology; Willis et al. (2022) npj Parkinson’s Disease; Yang et al. (2020) npj Parkinson’s Disease.
Navigation: ← What Is PD? | Symptoms →